Name

ATRA-IV

Alternate Names

Vesanoid

Abbreviations

None

Category

Differentiation inducing agent

Subcategory

Retinoid: please see Remarks for coding instructions

NSC Number

None

Primary Site

Lymphoma
Acute promyelocytic leukemia

Histology

None

Remarks

Atra is currently in clinical trials for Head & Necks cancers. It is under investigation as treatment of Kaposi Sarcoma. DO NOT CODE ATRA has treatment for these sites/histologies until FDA approval. Code as either 2, 3, or 6 in Other Therapy field.

ATRA has received FDA approval for treatment of Acute Promyelocytic Leukemia (APL). ATRA should be coded "1" in Other Therapy field.

Liposomal all-trans retinoic acid. Antigenics, Inc.

Coding

This drug should be coded
Glossary